Work

Abstract P3-14-20: Phase 1 Dose-Escalation Study of the Investigational HER2/EGFR Inhibitor TAK-285 in Patients with Advanced Cancer

Year: 2010

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs10-p3-14-20

Authors: P LoRusso, EG Chiorean, E Heath, A Weise, M Foley, YS Olivo, X Chi, M Corvez, K Venkatakrishnan, E. Sausville

Institutions: The Barbara Ann Karmanos Cancer Institute, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Takeda Oncology (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2064468259

Cites:

Cited by:

Related to: 10